Biggest News Aggregation in the World
📰 Primary Efficacy News

Primary Efficacy News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Primary Efficacy. Real-time updates on events, politics, business and more.

Horizon Therapeutics plc: Sustained Patient Response to KRYSTEXXA (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial

-- Month 12 results from MIRROR randomized controlled trial to be featured on Nov. 13, 11:45 a.m. EST during plenary session at the American College of Rheumatology Convergence 2022 -- -- Imaging
United States Amanda Phraner Clin Rheumatol Tina Ventura Johnk Botson Ada Kumar

Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease

-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the... | November 5, 2022
United States Brad Marder Clin Rheumatol Abdul Abdellatif Patients With Uncontrolled Gout Co Exchange Commission

Horizon Therapeutics plc: Data Support the Use of KRYSTEXXA (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease

-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the treatment
United States Brad Marder Amanda Phraner Clin Rheumatol Tina Ventura Abdul Abdellatif

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled G

-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the treatment period --DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate K...
United States Brad Marder Amanda Phraner Clin Rheumatol Tina Ventura Abdul Abdellatif

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia
United States East Hanover Novartis Scemblix Isabella Zinck Jeff Legos Thomas Hungerbuehler

Novartis Pharma AG: Novartis Scemblix demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix (asciminib) vs. Bosulif* (bosutinib) and lower discontinuation rate due to adverse
United States East Hanover Isabella Zinck Jeff Legos Thomas Hungerbuehler Floriana Riccio Furnari

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science